Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first
OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration …

Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with
potential to provide greater clinical benefit to patients with advanced-stage cancer. In …

Chimeric antigen receptor (CAR)–engineered T cell therapy for solid tumors is limited by the
lack of both tumor-restricted and homogeneously expressed tumor antigens. Therefore, we …

In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy.
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …

As one of the common cancers that threaten human life, the recurrence and metastasis of
colorectal cancer seriously affect the prognosis of patients. Although new drugs and …

Introduction: In recent years, various nanoparticles (NPs) have been discovered and
synthesized for the targeted therapy of cancer cells. Targeted delivery increases the local …

Triple-negative breast cancer is the most aggressive subtype of breast cancer and is difficult
to treat. Breast cancer is considered to be poorly immunogenic and hence is less responsive …

Although it is known that oncolytic viruses can inflame and recruit immune cells to otherwise
immunosuppressed tumor microenvironments, the influence of the antiviral immune …

Simple Summary Triple-negative breast cancer (TNBC) is an aggressive as well as the most
dangerous form of breast cancer. Due to the lack of biomarkers that can be targeted by …

Background Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma
(PDAC) is fatal. Our preclinical study presents an effective treatment against PDAC PC using …